Feasibility and Safety of ALVAC-HIV vCP1521 Vaccine in HIVexposed Infants in Uganda: Results from the First HIV Vaccine Trial in Infants in Africa

Simple item page
dc.contributor.authorKintu, Kenneth Guay
dc.contributor.authorAndrew, Philip
dc.contributor.authorMusoke, Philippa
dc.contributor.authorRichardson, Paul
dc.contributor.authorAsiimwe- Kateera, Brenda
dc.contributor.authorNakyanzi, Teopista
dc.contributor.authorWang, Lei
dc.contributor.authorGlenn Fowler, Mary
dc.contributor.authorEmel, Lynda
dc.contributor.authorOu, San-San
dc.contributor.authorBaglyos, Lynn
dc.contributor.authorGurunathan, Sanjay
dc.contributor.authorZwerski, Sheryl
dc.contributor.authorJackson, J. Brooks
dc.contributor.authorGuay, Laura
dc.date.accessioned2022-08-22T20:17:27Z
dc.date.available2022-08-22T20:17:27Z
dc.date.issued2013
dc.description.abstractThe development of a safe and effective vaccine against human immunodeficiency virus type 1 (HIV-1) for prevention mother-to-child transmission of HIV would significantly advance the goal of eliminating HIV infection in children. Safety and feasibility results from Phase I, randomized, double blind, placebo-controlled trial of ALVACHIV vCP1521 in infants born to HIV-1-infected women in Uganda are reported. Methods—HIV exposed infants were enrolled at birth and randomized (4:1) to receive vaccine or saline placebo intramuscular injections at birth, 4, 8 and 12 weeks of age. Vaccine reactogenicity was assessed at vaccination, and days 1 and 2 post-vaccination. Infants were followed until 24 months of age. HIV infection status was determined by HIV DNA PCR. Findings—From October 2006 to May 2007, 60 infants (48 vaccine, 12 placebo) were enrolled with 98% retention at 24 months. One infant was withdrawn, but there were no missed visits or vaccinations among the 59 infants retained. Immune responses elicited by Diptheria, Polio, Hepatitis B and Heamophilus influenzae type B and measles vaccination were similar in the two arms. The vaccine was well tolerated with no severe or life-threatening reactogenicity events. Adverse events were equally distributed across both study arms. Four infants were diagnosed as HIV infected [3 at birth (2 vaccine, 1 placebo) and one in vaccine arm at 2 weeks of age]. Interpretation—The ALVAC-HIV vCP1521 vaccination was feasible and safe in infants born to HIV-infected women in Uganda. The conduct of high quality infant HIV vaccine trials is achievable in Africa.en_US
dc.identifier.citationKintu, K., Andrew, P., Musoke, P., Richardson, P., Asiimwe-Kateera, B., Nakyanzi, T., ... & Guay, L. (2013). Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa. Journal of acquired immune deficiency syndromes (1999) , 63 (1), 1. doi:10.1097/QAI.0b013e31827f1c2d.en_US
dc.identifier.other10.1097/QAI.0b013e31827f1c2d.
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/4374
dc.language.isoenen_US
dc.publisherJournal of acquired immune deficiency syndromesen_US
dc.subjectHIV vaccineen_US
dc.subjectALVACen_US
dc.subjectInfantsen_US
dc.subjectAfricaen_US
dc.subjectBreast milk transmissionen_US
dc.titleFeasibility and Safety of ALVAC-HIV vCP1521 Vaccine in HIVexposed Infants in Uganda: Results from the First HIV Vaccine Trial in Infants in Africaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Feasibility and Safety of ALVAC-HIV vCP1521 Vaccine in HIVexposed Infants in Uganda.pdf
Size:
1.4 MB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences